306 generics · 531 brands
Most drug companies are built by businessmen, but Ibn Sina Pharma grew out of a charity. The Ibn Sina Trust, known for its hospitals and diagnostic centres, is its largest shareholder with about 44% of the shares. The company was founded in 1983, began commercial production in 1986 and was listed in 1989.
Over the years, it kept adding new lines. Eye care medicines came in 1995, herbal and natural medicines in 2008, and a dedicated cephalosporin antibiotic plant in 2016. Among its widely used brands are Gavisol, Dexlan, Xorel and Neuralgin, covering stomach acid, nerve pain and similar everyday complaints.
About 5,200 people work for the company, and its revenue was around Tk 1,348 crore in the 12 months to March 2026. Almost all of that comes from Bangladesh, with exports still a very small share.
The next stage is about diversification. Ibn Sina has announced plans to form subsidiaries for active pharmaceutical ingredients, polymers, consumer products and biotechnology, and two Chinese companies have signed technology transfer agreements with it. It is also building new factories and product lines.